Introduction Executive Summary Hepatic encephalopathy: Overview ● Causes ● Mechanism of Action ● Signs and Symptoms ● Diagnosis ● Disease Management Pipeline Therapeutics ● Comparative Analysis Therapeutic Assessment ● Assessment by Product Type ● Assessment by Stage and Product Type ● Assessment by Route of Administration ● Assessment by Stage and Route of Administration ● Assessment by Molecule Type ● Assessment by Stage and Molecule Type Hepatic encephalopathy – DelveInsight’s Analytical Perspective In-depth Commercial Assessment ● Hepatic encephalopathy companies’ collaborations, Licensing, Acquisition -Deal Value Trends Hepatic encephalopathy Collaboration Deals ● Company-Company Collaborations (Licensing / Partnering) Analysis ● Company-University Collaborations (Licensing / Partnering) Analysis Late Stage Products (Phase III) ● Comparative Analysis MNK-6105: Mallinckrodt ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) ● Comparative Analysis RBX7455: Rebiotix Inc. ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Early Stage Products (Phase I) ● Comparative Analysis Drug Name: Company Name ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Preclinical Stage Products ● Comparative Analysis Neur-001: Neuractas therapeutics ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Inactive Products ● Comparative Analysis Hepatic encephalopathy Key Companies Hepatic encephalopathy Key Products Hepatic encephalopathy- Unmet Needs Hepatic encephalopathy- Market Drivers and Barriers Hepatic encephalopathy- Future Perspectives and Conclusion Hepatic encephalopathy Analyst Views Hepatic encephalopathy Key Companies Appendix

Table 1 Total Products for Hepatic encephalopathy Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• Surrozen • Axcella health • Versantis AG • Rebiotix Inc. • Mallinckrodt • Sigyn Therapeutics • Kaleido Biosciences, Inc. • Neuractas Therapeutics